In light of the recent US Food and Drug Administration (FDA) warning to device manufacturers, the aesthetic medical business experts at Acara Partners decided to review our financial analysis of the feasibility and profitability of vaginal rejuvenation. Coupling our analysis of the financials with a variety of response statements in the industry has solidified our sustained recommendation – properly trained physicians should continue to add vaginal therapy services to their aesthetic medical practices.

How to Interpret the FDA Warning

The FDA recently released a warning regarding manufacturers’ “inappropriate marketing of their devices” for vaginal rejuvenation services. The warning noted that while these devices are FDA-cleared for certain medical purposes, they are being marketed for services and treatments related to vaginal rejuvenation, for which they do not currently have clearance.

Read more at Acara Partners >>